HIGHLIGHTS
- who: Hao Zhaohu and colleagues from the Tianjin, China NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases have published the Article: Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China, in the Journal: Journal of Diabetes Research 80% 70% of 13/08/2022
- what: The authors aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.